A PHASE 2 SINGLE ARM STUDY OF CARFILZOMIB IN TRANSPLANT ELIGIBLE HIGH RISK MULTIPLE MYELOMA
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Jun 2018
Price : $35 *
At a glance
- Drugs Carfilzomib (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 17 Jun 2018 Preliminary results (data cut off: 31 Dec, 2017; n=30) presented at the 23rd Congress of the European Haematology Association.
- 17 Apr 2018 Planned End Date changed from 1 Sep 2018 to 1 Dec 2020.
- 17 Apr 2018 Planned primary completion date changed from 1 Sep 2016 to 1 Dec 2019.